Anthem Biosciences Ltd
Anthem Biosciences Limited operates as technology-focused contract research, development, and manufacturing organization. It operates through two segments: Contract Research, Development & Manufacturing (CRDMO) services; and Speciality Ingredients. The company offers end-to-end services across the new chemical entity and new biological entity lifecycles, including target identification and the co… Read more
Anthem Biosciences Ltd (ANTHEM) - Total Assets
Latest total assets as of September 2025: ₹32.84 Billion INR
Based on the latest financial reports, Anthem Biosciences Ltd (ANTHEM) holds total assets worth ₹32.84 Billion INR as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Anthem Biosciences Ltd - Total Assets Trend (2022–2025)
This chart illustrates how Anthem Biosciences Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Anthem Biosciences Ltd - Asset Composition Analysis
Current Asset Composition (March 2025)
Anthem Biosciences Ltd's total assets of ₹32.84 Billion consist of 61.9% current assets and 38.1% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 11.3% |
| Accounts Receivable | ₹4.60 Billion | 16.4% |
| Inventory | ₹3.40 Billion | 12.1% |
| Property, Plant & Equipment | ₹0.00 | 0.0% |
| Intangible Assets | ₹38.71 Million | 0.1% |
| Goodwill | ₹0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how Anthem Biosciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Anthem Biosciences Ltd's current assets represent 61.9% of total assets in 2025, a decrease from 67.5% in 2022.
- Cash Position: Cash and equivalents constituted 11.3% of total assets in 2025, down from 21.1% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2022.
- Asset Diversification: The largest asset category is accounts receivable at 16.4% of total assets.
Anthem Biosciences Ltd Competitors by Total Assets
Key competitors of Anthem Biosciences Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx SE
OTCGREY:ARGNF
|
USA | $7.18 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Exicure Inc
NASDAQ:XCUR
|
USA | $15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Anthem Biosciences Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Anthem Biosciences Ltd generates 0.66x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Anthem Biosciences Ltd generates $ 16.07 in net profit.
Anthem Biosciences Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.71 | 4.56 | 4.38 |
| Quick Ratio | 4.31 | 3.57 | 3.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₹17.20 Billion | ₹ 13.15 Billion | ₹ 11.43 Billion |
Anthem Biosciences Ltd - Advanced Valuation Insights
This section examines the relationship between Anthem Biosciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 17.07 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 17.1% |
| Total Assets | ₹28.08 Billion |
| Market Capitalization | $17.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Anthem Biosciences Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Anthem Biosciences Ltd's assets grew by 17.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Anthem Biosciences Ltd (2022–2025)
The table below shows the annual total assets of Anthem Biosciences Ltd from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | ₹28.08 Billion | +17.07% |
| 2024-03-31 | ₹23.98 Billion | +19.05% |
| 2023-03-31 | ₹20.14 Billion | +24.44% |
| 2022-03-31 | ₹16.19 Billion | -- |